These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 11062025

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.
    Pagano E, Calvo JC.
    J Cell Biochem; 2003 Oct 15; 90(3):561-72. PubMed ID: 14523990
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Altered gene expression in drug-resistant human breast cancer cells.
    Wosikowski K, Schuurhuis D, Kops GJ, Saceda M, Bates SE.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 1):2405-14. PubMed ID: 9815641
    [Abstract] [Full Text] [Related]

  • 8. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 9. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK.
    Breast Cancer Res Treat; 2006 Jan 01; 95(1):17-27. PubMed ID: 16267617
    [Abstract] [Full Text] [Related]

  • 10. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 01; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 11. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 01; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

  • 12. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
    Xia W, Liu LH, Ho P, Spector NL.
    Oncogene; 2004 Jan 22; 23(3):646-53. PubMed ID: 14737100
    [Abstract] [Full Text] [Related]

  • 13. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.
    Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS.
    Clin Cancer Res; 2001 Jul 22; 7(7):1957-62. PubMed ID: 11448910
    [Abstract] [Full Text] [Related]

  • 14. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
    Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH.
    Oncogene; 1995 May 04; 10(9):1813-21. PubMed ID: 7538656
    [Abstract] [Full Text] [Related]

  • 15. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
    Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC.
    Oncogene; 1998 Apr 23; 16(16):2087-94. PubMed ID: 9572489
    [Abstract] [Full Text] [Related]

  • 17. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
    Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC.
    Oncogene; 1996 Sep 19; 13(6):1359-65. PubMed ID: 8808711
    [Abstract] [Full Text] [Related]

  • 18. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
    Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE.
    Cancer Res; 1997 Sep 01; 57(17):3804-11. PubMed ID: 9288791
    [Abstract] [Full Text] [Related]

  • 19. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C, Borghouts C, Buerger C, Groner B.
    Mol Cancer Res; 2006 Dec 01; 4(12):983-98. PubMed ID: 17189388
    [Abstract] [Full Text] [Related]

  • 20. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A.
    Oncol Rep; 2007 Feb 01; 17(2):465-9. PubMed ID: 17203189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.